[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@chuminhua432 Avatar @chuminhua432 Minhua Chu

Minhua Chu posts on X about hong kong, china, ipo, hong kong stock exchange the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXX% travel destinations XXXX% finance XXXX% countries XXXX% exchanges #1791 vc firms #661 currencies XXXX% cryptocurrencies XXXX% technology brands XXXX%

Social topic influence hong kong #194, china 1.91%, ipo #97, hong kong stock exchange #1, approved #186, hong 0.96%, kong 0.96%, has been 0.96%, listing #256, idg capital #3

Top accounts mentioned or mentioned by @yaireinhorn @knielsen2000 @maverickny @dtrmweihe @awodajo @phototogboy @jbdotdotdot @bioebro @sss124545852740 @grok @fiercebiotech @yahoofinance @ceo_culley @exclamotite69 @drcm4t @taylor_hibbs_ @lenni1976 @snupsnus @glptrackerapp @jacobplieth

Top assets mentioned Bristol-Myers Squibb Co (BMY) Johnson & Johnson (JNJ) GSK plc (GSK) Eli Lilly and Company (LLY) One Cash (ONC) AbbVie Inc (ABBV) Gilead Sciences, Inc. (GILD) Sanofi (SNY) Synthetify (SNY) Novo-Nordisk (NVO)

Top Social Posts #

Top posts by engagements in the last XX hours

"Xuanzhu Bio a spin-off from Sihuan Pharmaceutical (a HKSE listed pharma) based in Shijiazhuang Hebei has successfully listed on the main board of the Hong Kong Stock Exchange. #ipo For this IPO Xuanzhu offered a global sale of XXXXXXX million H shares (accounting for XX% of the total shares post-issuance) at a price of HK$11.60 per share raising gross proceeds of approximately HK$781 million with net proceeds of about HK$701 million. The offering saw the public tranche oversubscribed by 4908.33 times and the international tranche by XXXXX times. On the eve of listing the stock closed at"
X Link @chuminhua432 2025-10-15T10:14Z 2900 followers, XXX engagements

"$DNTH a clinical-stage bio announced it has entered into an exclusive #licensing agreement with Nanjing Leads Biolabs for DNTH212 (being developed in China by Leads Biolabs as LBL-047) a first and potentially best-in-class bifunctional BDCA2 and BAFF/APRIL inhibitor. DNTH212 is an investigational extended half-life bifunctional fusion protein. Now in Ph1. $XX million upfront + near-term milestone payments $X million milestone upon the initiation of a Dianthus-led Phase X study additional $XXX million in total development and regulatory approval milestones and sales-based milestones"
X Link @chuminhua432 2025-10-17T07:02Z 2902 followers, 1337 engagements

"China Biopharma Tracker - September 2025 #financing #ChinabioTracker In Sept. China private biotech reported XX financing deals totaled $500m only XX disclosed the amounts the number and amount is similar to prior months Aug. 30/22 $560m Jul. 23/17 $481m The three months of Q3 marked a significant rebound in financing amounts following nearly three years of weakness. The biggest financing in Sept. is TJ Biopharma I-mab spin-off Chinese bio raised nearly RMB XXX million in Series C2 led by CITIC Capital. One biotech GenFleet Therapeutics completed its IPO in HKSE IPO application frenzy: 12"
X Link @chuminhua432 2025-10-07T15:53Z 2902 followers, 1177 engagements

"$GSK announced that the NMPA has approved Shingrix (GSKs Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster) in adults aged XX years and over who are at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy. the previous indication for adults aged XX and older"
X Link @chuminhua432 2025-10-15T09:55Z 2900 followers, XXX engagements

"Kailera Therapeutics Announces $XXX Million Series B Financing Kailera Therapeutics details of which first emerged in May 2024 under the name Hercules CM NewCo emerged from stealth Tuesday with plans to develop a portfolio of GLP-1 drugs. The drugs were acquired from Jiangsu Hengrui Pharmaceuticals"
X Link @chuminhua432 2025-10-15T09:28Z 2902 followers, 1018 engagements

"#Innovent Biologics' clinical trial application for #IBI3026 has been accepted by the #NMPA. IBI3026 is a fusion protein of a PD-1 antibody and IL-12. Some key facts about IBI 3026:"
X Link @chuminhua432 2025-08-22T14:32Z 2900 followers, 1249 engagements

"#MagicRNA announced the completion of nearly RMB100 million in Pre-A+ #financing led by IDG Capital. The funds will be used for the IND filing and IITs of the lead asset #HN2301. Founded in December 2021 MagicRN focuses on nucleic acid drug delivery and therapeutic mRNA innovative drugs. The company has developed a ionizable amino lipid library with the lipid (ILB3132) already commercialized. In 2023 MagicRNA successfully established an engineered cell delivery platform (Engineered Cell Targeted LNP EnC-LNP). The in vivo CAR-T HN2301 developed based on the EnC-LNP platform enter the clinical"
X Link @chuminhua432 2025-08-29T09:59Z 2902 followers, 7420 engagements

"CF PharmaTech officially lists on the Hong Kong Stock Exchange today. Joint sponsors for this IPO are CITIC Securities and CMB International with an issue price of HK$14.75 per share and net proceeds of HK$525.4 million. CF PharmaTech opened at HK$47 per share closing at HK$38.50 up 161.02%"
X Link @chuminhua432 2025-10-08T12:37Z 2900 followers, XXX engagements

"#Innovent Biologics' dual glucagon/GLP-1 receptor agonist #mazdutide has been approved for a new indication for marketing for glycemic control in adult patients with type X diabetes. Previously the drug has been approved for long-term weight management in adult patients with obesity or overweight. Innovent licensed mazdutide from Eli Lilly"
X Link @chuminhua432 2025-09-19T16:38Z 2899 followers, 1207 engagements

"Eccogene Inc. submitted its Hong Kong IPO listing application documents with joint sponsors Jefferies BofA Securities and CICC. Founded in 2018 Eccogene has pipeline including GLP-1 receptor agonists THR- agonists SSAO (VAP-1) inhibitors GIP receptor modulators and Amylin receptor agonists. Eccogene's Series C financing in Dec. 2023 resulted in a post-money valuation of $XXX million. In Nov. 2023 Eccogene signed an agreement with AstraZeneca on the small molecule oral GLP-1 agonist ECC5004. Eccogene granted AstraZeneca exclusive rights to develop and commercialize ECC5004 (for any indication)"
X Link @chuminhua432 2025-10-08T14:11Z 2900 followers, 1248 engagements

"$ONC and $ABBV s Pharmacyclics have decided to voluntarily dismiss the patent lawsuit the Big Pharma firm brought against its competitor over their BTK inhibitors. BeOne announced the decision in a securities filing to HKSE. The move comes after the U.S. Patent and Trademark Office (USPTO) recently invalidated all claims of AbbVies patent No. 11672803 which underpinned the Illinois pharmas patent infringement lawsuit filed in 2023"
X Link @chuminhua432 2025-10-03T15:36Z 2902 followers, XXX engagements

"On Oct XX Biokin/SystImmune announced that the global Phase 2/3 pivotal registration clinical trial IZABRIGHT-Breast01 for its iza-bren (BL-B01D1 EGFRHER3 bispecific ADC) in collaboration with $BMY has achieved a milestone triggering the first $XXX million near-term contingent payment condition under the BMS collaboration agreement. The wholly-owned subsidiary SystImmune will receive the payment"
X Link @chuminhua432 2025-10-13T10:22Z 2900 followers, XXX engagements

"#esmo2025 oral Biokin/SystImmune EGFR x HER3 ADC Iza-Bren (BL-B01D1) Phase I global study of Iza-Bren (BL-B01D1) an EGFR x HER3 bispecific antibody-drug conjugate (ADC) in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and other solid tumors D1D8 Q3W is summarized in the table. Promising efficacy was observed at XXX mg/kg in multiple tumor types with confirmed ORR (cORR) of XXXX% including NSCLC (cORR XXXX% N=14; cORR XXXX% for EGFR mutant N=11 and cORR XXXX% for EGFR wildtype N=3) and BC (cORR XXX% N=3)"
X Link @chuminhua432 2025-10-13T09:58Z 2902 followers, 2283 engagements

"#Minova Pharma completed a hundred-million RMB level Series B #financing exclusively led by IDG Capital. Minova's homegrown DCA (deoxycholic acid) injection wasapproved for market in China in June becoming China's first aproved fat-dissolving injection. The company continues to focus on the field of aesthetic-related diseases with new drugs for s androgenetic alopecia and photoaging set to enter clinical development in Q4 2025. In the field of mental health the anti-postpartum depression drug MI078 capsule has completed Phase II clinical studies"
X Link @chuminhua432 2025-08-25T06:12Z 2902 followers, XXX engagements

"While $IMAB's press release describes VIS-101 "to be acquired by Visara" ASK Pharma's Chinese listing announcement refers to it as a licensing agreement in licensed territories. According to ASK its controlling subsidiary AskGene Pharma has entered into a licensing agreement with Visara. AskGene Pharma grants Visara rights of its ASK G712 (VIS-101) within the licensed territories. The licensed regions include Greater China Singapore Thailand Malaysia Indonesia Vietnam South Korea and India. Visara will pay AskGene a one-time non-refundable upfront payment of $X million within XX business days"
X Link @chuminhua432 2025-10-17T17:07Z 2902 followers, 1012 engagements

"Legend Biotech $LEGN registered a Phase I clinical trial for LUCAR-G19 to treat autoimmune diseases. NCT07049081 The study plans to enroll XX patients with relapsed or refractory autoimmune diseases including systemic lupus erythematosus systemic sclerosis ANCA-associated vasculitis inflammatory myopathy Takayasu arteritis IgG4-related disease. The study has X sites in #China. LUCAR is a non-gene-editing allogeneic CAR-T technology platform independently developed by Legend Biotech. It employs endogenous TCR silencing technology blocking complex formation by expressing proteins that"
X Link @chuminhua432 2025-07-04T09:07Z 2900 followers, 2835 engagements

"Tibet #Rhodiola Pharma announced its plan to establish a wholly-owned subsidiary in Hong Kong TopRidge Pharma Limited to make an equity investment in AccurEdit Therapeutics. The investment amounts to US$60 million securing a XXXXX% equity stake. Additionally CMS Medical Venture Investment an affiliate of s major shareholder will invest US$15 million acquiring a XXXXX% equity stake. AccurEdit Therapeutics focuses on developing in vivo gene editing technologies and products based on Lipid Nanoparticle (LNP) and other non-viral vectors. The companys core assets andoperations are centered on"
X Link @chuminhua432 2025-08-27T15:41Z 2901 followers, 1502 engagements

"$GILD s Kite Pharma is doubling down on in vivo CAR-T this time inking a deal worth up to $XXXX billion biobucks with biotech Pregene Biopharma. $XXX million upfront + $XXXX billion milestone Pregene also helped AstraZeneca-owned EsoBiotec design its in vivo CAR-T. The Big Pharma bought out EsoBiotec back in March for up to $X billion dollars"
X Link @chuminhua432 2025-10-17T07:36Z 2902 followers, 2186 engagements

"Today's 3rd biopharma out-licensing deal: Hansoh Pharma grants Roche an exclusive worldwide license (excluding the Chinese Mainland Hong Kong Macau and Taiwan) to its investigational CDH17-targeting ADC HS-20110. Hansoh Pharmawill receive an upfront payment of US$80 million and is eligible to receive milestone payments as well as royalties on potential future product sales. HS-20110 a CDH17-targeting ADCutilizing TOPOi payload. In Ph1 study for solid tumor"
X Link @chuminhua432 2025-10-17T15:55Z 2902 followers, 1392 engagements

"China Biopharma Tracker - September 2025 #apprvoal #ChinabioTracker Only X new novel drugs received their first marketing approval in September by China's NMPA both are from ex-China 1) Tzield (teplizumab) $SNY CD3 mab for type X diabetes 2) Fexuclue (fexuprazan) P-CAB Yangtze River Pharma licensed from Daewoong Pharma for gastroesophageal reflux disease X drugs approved for new indication including Mazdutide dual glucagon/GLP-1 receptor agonist for T2DM Innovent licensed the drug from $LLY And denosumab biosimiliar from Henlius Fosun' subsidiary appproved in both US and Europe in September"
X Link @chuminhua432 2025-10-06T14:38Z 2900 followers, 3307 engagements

"On Sept. XX TJ Biopharma announced the completion of nearly RMB XXX million in Series C2 financing. This round was led by a fund under CITIC Capital. The raised funds will primarily support the Ph3clinical trials and marketing applications for tier1 pipelines accelerating the R&D of tier2 pipelines. Tier1 pipeline: X products in marketing application and late-stage clinical phases - Felzartamab: A differentiated domestically produced CD38 antibody its marketing application for multiple myeloma has been accepted -Eftansomatropin Alfa: An innovative fully fused long-acting growth hormone its"
X Link @chuminhua432 2025-10-02T16:32Z 2900 followers, XXX engagements

"$JNJ reported 2025 Q3 earnings XXX% sales increase to $XX billion BCMA CAR-T therapy Carvyktideveloped in partnership with Legend Biotechsaw significant sales growth. Carvykti achieved total sales of $XXX million in Q3 2025 marking an XXXX% yoy increase. Carvykti's sales have already surpassed $X billion this year totaling $XXXXX billion exceeded its full-year total from 2024 which was $XXX million"
X Link @chuminhua432 2025-10-15T09:43Z 2902 followers, 2741 engagements

"A good series by @FierceBiotech about $NVO vs KBP Biosciences founded by Zhenhua Huang FierceBiotech went through thousands of pages of sealed court documents"
X Link @chuminhua432 2025-10-16T14:55Z 2902 followers, XXX engagements

"Some media reported that Legend Biotech $LEGN has disbanded its Chinese sales and marketing team. On August XX 2024 #Carvykti (cilta-cel) was approved for marketing in #China becoming the sixth CAR-T cell therapy to be launched in China. In 2024 Carvykti's global sales revenue was $XXX million. $JNJ"
X Link @chuminhua432 2025-06-16T10:09Z 2902 followers, 1412 engagements

"A rumor suggests that $BMY may be poised for a major adjustment in its #China operations. According to the content of a leaked email BMS has signed an agreement to sell its XX% stake in Shanghai Bristol-Myers Squibb Pharmaceutical Co. Ltd. (SASS) along with several related products manufactured and sold exclusively in the mainland China marketincluding Baraclude (entecavir) Bufferin Theragran Monopril (fosinopril) and Velosef (cephradine)to an affiliate of Hillhouse Investment Group (Highland Capital). The transaction is expected to be completed in early 2026 with the specific deal amount yet"
X Link @chuminhua432 2025-09-13T08:23Z 2902 followers, 13.7K engagements

"$IMAB announced its intention to pursue a Hong Kong IPO through dual listing on NASDAQ and Hong Kong Stock Exchange (HKEX). The Company intends to operate under the new name of NovaBridge Biosciences. The Company also announced the pending acquisition of VIS-101 a novel bifunctional biologic targeting VEGF-A and ANG2. The pending acquisition will be made by a newly formed subsidiary Visara Inc. (Visara) a NewCo focused on developing ophthalmic therapeutics for serious eye disorders and is expected to be completed later this month. VIS-101 (also named lASKG712) is developed by ASK pharma the"
X Link @chuminhua432 2025-10-17T16:56Z 2902 followers, 1604 engagements

"#esmo2025 oral Multitude Therapeutics CD44v9 ADC AMT-116 Updated ongoing phase I/II clinical trial results of AMT-116 a first-in-class anti-CD44v9 antibody-drug conjugate (ADC) in patients with advanced solid tumors X mg/kg Q2W was determined as the RP2D dose in AMT-116-02 Among EGFR wild-type NSCLC patients (n=20; squamous/non-squamous) the objective response rate was XX% (6/20 X confirmed PR) and the disease control rate was XX% (17/20). TRAEs Grade X occurred in XXXX% of patients"
X Link @chuminhua432 2025-10-13T10:05Z 2902 followers, XXX engagements

"Kelun-BiotechBiopharmaceuticalannouncedthat the Company's HER2-directed ADC trastuzumab botidotin (A166) was approved for marketing by NMPA for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (BC) who have received one or more prior anti-HER2 therapy. Trastuzumab botidotinconjugates a novel monomethyl auristatin F(MMAF)derivative (a highly cytotoxic tubulin inhibitor Duo-5) via a stable enzyme-cleavable linker to a HER2 monoclonal antibody with a drug-to-antibody-ratio (DAR) of 2"
X Link @chuminhua432 2025-10-17T15:42Z 2902 followers, XXX engagements

"#Innovent Biologics announced Friday that #mazdutide a dual #glucagon/GLP-1 receptor agonist licensed from $LLY in 2019 was approved by Chinese #NMPA for chronic weight management in adults with overweight or obesity. The decision was based on data from the Chinese Phase III GLORY-1 trial which were presented #ADA2024 At week XX those taking the high dose saw placebo-adjusted weight loss of XX% which increased to XXXX% at week XX. Mazdutide is under NMPA review for type X diabetes In DREAMS-2 the high dose of mazdutide lowered HbA1c by XXXX% from baseline at XX weeks versus XXXX% for Trulicity"
X Link @chuminhua432 2025-06-28T07:59Z 2900 followers, 1291 engagements